Welcome to our dedicated page for QT Imaging Holdings news (Ticker: qti), a resource for investors and traders seeking the latest updates and insights on QT Imaging Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect QT Imaging Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of QT Imaging Holdings's position in the market.
QT Imaging (Nasdaq: QTI) CEO Dr. Raluca Dinu spoke at the inaugural Shiftmakers Gala at Harvard on March 27, 2026, emphasizing early breast cancer detection and the limits of mammography for women with dense breast tissue.
The company said its radiation-free imaging advances will be featured in The Shift to broaden awareness and reach more women and clinicians.
QT Imaging (Nasdaq: QTI) released image reconstruction software version 4.5.0 on April 1, 2026, improving spatial resolution and performance for challenging breast imaging cases.
Enhancements include spatially varying deconvolution, fusion of speed of sound and reflection data, better small-breast reconstruction, and improved assessment with implants.
QT Imaging (Nasdaq: QTI) reported 2025 revenue of $18.9 million, a record aided by shipping 40 scanners and exceeding guidance. The company affirmed 2026 revenue guidance of ~$39 million, citing contracted MOQs and initial QTI Cloud Platform revenue.
Key developments include AMA Category III CPT code approval (effective Jan 1, 2027), FDA 510(k) clearance for an updated scanner configuration, Nasdaq relisting, an $18.2 million private placement, and distribution agreements guaranteeing minimum orders in the UAE totaling 43 scanners (>$24 million revenue).
QT Imaging (Nasdaq: QTI) received UAE Emirates Drug Establishment clearance for its Breast Acoustic CT scanner, allowing importation, distribution, and marketing to licensed UAE healthcare facilities.
QT Imaging signed an exclusive UAE distribution deal with Al Naghi Medical and reported a $24 million revenue pipeline through 2028, expanding its commercial presence in the Middle East.
QT Imaging (Nasdaq: QTI) will report results for the three and 12 months ended December 31, 2025 and hold a conference call on March 25, 2026 at 4:30 p.m. ET (1:30 p.m. PT).
Pre-registration is available for immediate access; dial-in numbers are provided for U.S. and international participants. A live and archived webcast will be available on the company investor relations calendar.
QT Imaging (Nasdaq: QTI) received FDA 510(k) clearance on March 10, 2026 for an enhanced configuration of its Breast Acoustic CT scanner that improves visualization and expands coverage of posterior breast tissue.
The update uses a tilted transmitter geometry to better image breast tissue near the chest wall and continues to generate 3D tomographic images with quantified fibroglandular tissue volume (FGV) and FGV-to-total-breast-volume metrics.
QT Imaging (Nasdaq: QTI) appointed Dr. Mary W. Yamashita as Medical Advisor effective March 4, 2026. Dr. Yamashita will advise on clinical interpretation standards, structured reporting, training, and reader study design to support clinical integration of QT Imaging’s radiation-free 3D breast imaging technology.
She is Section Chief of Breast Imaging at USC Keck School of Medicine and Medical Director of mammography at two USC breast centers; her experience includes multicenter trials, research, and resident/fellow mentorship.
QT Imaging (Nasdaq: QTI) announced AMA approval of a new Category III CPT code X579T for 3D quantitative transmission volumetric ultrasound tomography of the breast. The code will be released July 1, 2026, and becomes effective January 1, 2027, enabling standardized reporting and commercial opportunities with hospitals.
The designation recognizes the technology as a distinct clinical service, supports utilization tracking and data collection, and is described as a step toward broader reimbursement and adoption.
QT Imaging (Nasdaq: QTI) reported preliminary unaudited results for Q4 and full year 2025. Q4 revenue $8.3M on shipments of 17 scanners; 2025 revenue $18.9M on 40 scanners, above $18.0M guidance. Gross margin declined to 45% for 2025; cash and equivalents $10.5M as of Dec 31, 2025.
Strengthened capital with a $18.2M private placement, relisted on Nasdaq, and announced collaborations with Intelerad and Olea. Secured UAE distribution with committed minimum orders of 43 scanners (>$24M revenue). 2026 revenue outlook: ~$39M.
QT Imaging (NASDAQ: QTI) announced that Chief Science Officer Bilal Malik, Ph.D. will present at SPIE Medical Imaging 2026 in Vancouver, Feb 15–19, 2026. His oral talk, “Automated breast boundary extraction from reflection data in breast acoustic CT,” details a multi-step, validated algorithm integrated into company production software.
The method supports image reconstruction, reflection gain calculation, denoising, breast density calculation, and underpins planned AI/ML initiatives for lesion segmentation and clinical decision support.